You are here

Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Deep Vein Thrombosis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female patient of 18 - 70 years of age.

- Cancer patient with proven deep-vein thrombosis with or without pulmonary embolism
confirmed by combination of clinical signs and symptoms, pulmonary hypertension on
echocardiogram, X-ray examination of the lung and eventually perfusion/ventilation
scan of the lung.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Bleeding

- Hypersensitivity to FRAGMIN® or other low-molecular weight heparins.

- Serum creatinine level > 150 umol/l.

- Platelet count of less than 100 000 per cubic millimeter at the beginning of the
therapy.

- Patient on oral anticoagulation therapy in the last 7 days.

NCT00480636
Pfizer
Completed
Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now